Pre-Hospital Pulse Glucocorticoid Therapy in Patients with ST-Segment Elevation Myocardial Infarction Transferred for Primary Percutaneous Coronary Intervention: A Randomized Controlled Trial (PULSE-MI)

Author:

Madsen Jasmine Melissa1ORCID,Obling Laust Emil Roelsgaard1,Rytoft Laura1,Folke Fredrik2,Hassager Christian1,Andersen Lars Bredevang3,Vejlstrup Niels1,Bang Lia Evi1,Engstrøm Thomas1,Lønborg Jacob Thomsen1

Affiliation:

1. Rigshospitalet Hjertecentret: Rigshospitalet Center for Hjerte Kar Lunge og Infektionssygdomme

2. Herlev Hospital

3. Region Sjalland: Region Sjaelland

Abstract

Abstract Background Inflammation in ST-segment elevation myocardial infarction (STEMI) is an important contributor to both acute myocardial ischemia and reperfusion injury after primary percutaneous coronary intervention (PCI). Methylprednisolone is a glucocorticoid with potent anti-inflammatory properties with an acute effect and is used as an effective and safe treatment of a wide range of acute diseases. The trial aims to investigate the cardioprotective effects of pulse-dose methylprednisolone administered in the pre-hospital setting in patients with STEMI transferred for primary PCI. Methods This trial is a randomized, blinded, placebo-controlled prospective clinical phase II trial. Inclusion will continue until 378 patients with STEMI have been evaluated for the primary endpoint. Patients will be randomized 1:1 to a bolus of 250 mg methylprednisolone intravenous or matching placebo over a period of 5 minutes in the pre-hospital setting. All patients with STEMI transferred for primary PCI at Rigshospitalet, Copenhagen University Hospital, Denmark will be screened for eligibility. The main eligibility criteria are age ≥ 18 years, acute onset of chest pain with < 12 hours duration, STEMI on electrocardiogram, no known allergy to glucocorticoids or no previous coronary artery bypass grafting, previous acute myocardial infarction in assumed culprit, or a history with previous maniac/psychotic episodes. Primary outcome is final infarct size measured by late gadolinium enhancement on cardiac magnetic resonance (CMR) three months after STEMI. Secondary outcomes compromise key CMR efficacy parameters, clinical endpoints at three months, the peak of cardiac biomarkers, and safety. Discussion We hypothesize that pulse-dose methylprednisolone administrated in the pre-hospital setting decreases inflammation, and thus reduces final infarct size in patients with STEMI treated with primary PCI. Trial registration EU-CT number: 2022-500762-10-00; Submitted May 5, 2022. ClinicalTrials.gov Identifier: NCT05462730; Submitted July 7, 2022, first posted July 18, 2022

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3